PARP1 and head and neck squamous cell carcinoma: In addition to this, our ongoing experiments aim to examine the impact of PARP inhibition both alone, but particularly on the radiosensitisation of patient-derived HNSCC organoids, with a view to providing more preclinical evidence that this is a strategy that could be taken forward for future benefit of HNSCC patients.